

# CLINICAL PHARMACOLOGY and THERAPEUTICS

## **Editor**

Walter Modell, M.D.

## **Associate Editor**

Marcus M. Reidenberg, M.D.

## **Editorial Board**

Alvito P. Alvares, Ph.D.  
Wilbert S. Aronow, M.D.  
Arthur J. Atkinson, Jr., M.D.  
Daniel L. Azarnoff, M.D.  
Frank M. Berger, M.D., D.Sc.  
Karl H. Beyer, Jr., M.D., Ph.D.  
Hylan A. Bickerman, M.D.  
Terrence F. Blaschke, M.D.  
Donald B. Calne, M.D.  
Edward A. Carr, Jr., M.D.  
Allan H. Conney, Ph.D.  
T. S. Danowski, M.D.  
Arthur C. DeGraff, M.D.  
Peter Dineen, M.D.  
Edward F. Domino, M.D.  
Alvan R. Feinstein, M.D.  
Vladimir Fencl, M.D.  
Robert B. Forney, Ph.D.  
Emil Frei, III, M.D.  
Milo Gibaldi, Ph.D.  
Norton J. Greenberger, M.D.  
Leo E. Hollister, M.D.  
Bartholomew P. Hsi, Ph.D.  
Murray E. Jarvik, M.D.  
Ernest Jawetz, M.D., Ph.D.

Stanley A. Kaplan, Ph.D.  
Attallah Kappas, M.D.  
Arthur S. Keats, M.D.  
Richard H. Kessler, M.D.  
Kenneth G. Kohlstaedt, M.D.  
Henn Kutt, M.D.  
Louis Lasagna, M.D.  
Louis Lemberger, M.D., Ph.D.  
Gerhard Levy, Pharm.D.  
T. A. Loomis, M.D., Ph.D.  
David T. Lowenthal, M.D.  
Daniel S. Lukas, M.D.  
Arno G. Motulsky, M.D.  
Alan S. Nies, M.D.  
R. K. Richards, M.D.  
David G. Shand, M.B., Ph.D.  
Albert Sjoerdsma, M.D., Ph.D.  
Jay Tepperman, M.D.  
Max Tishler, Ph.D.  
Leroy D. Vandam, M.D.  
Elliot S. Vesell, M.D.  
Louis Weinstein, M.D.  
John G. Wagner, Ph.D.  
E. Leong Way, Ph.D.

**Volume 30, July-December, 1981**

**The C. V. Mosby Company, St. Louis**

Volume 30  
Copyright © 1981 by  
The C. V. Mosby Company

*All rights reserved*

*Printed in the United States of America*

## Index to volume 30

### Author index

#### A

- Aanonsen L: *see* Shand et al, 701  
Abeyasekera G: *see* Brodie et al, 363  
Actor P: *see* Pitkin et al, 587  
Akimoto T: *see* Nomura et al, 177  
Alexander F: *see* Pitkin et al, 587  
Alford RH: *see* Hawkins et al, 468  
Aliendres R: *see* Velasco et al, 158  
Alken RG: *see* Haegele et al, 210  
Allonen H, Ziegler G, Klotz U: Midazolam kinetics, 653  
Amsterdam EA: *see* Harris et al, 765  
Andreasen PB: *see* Døssing and Andreasen, 101  
Andrews-Figueroa P: *see* Velasco et al, 158  
Arita T: *see* Nomura et al, 177  
Asbury MJ: *see* McInnes et al, 218  
Ashley JJ: *see* Freedman et al, 644  
Awadzi K: *see* Edwards et al, 551  
Axthelm T: *see* Kirch et al, 429

#### B

- Baer-Weiss V: *see* Gritz et al, 201  
Ballard RH: *see* Miller et al, 343  
Barchowsky A: *see* Routledge et al, 154  
Barkley R: *see* Bauer et al, 35  
Bauer JH, Brooks CS, Weinstein I, Wilcox HH, Heimberg M, Burch RN, Barkley R: Effects of diuretic and propranolol on plasma lipoprotein lipids, 35  
Bekersky I: *see* Colburn et al, 559  
Benet LZ: *see* Smith et al, 105  
Benowitz NL: *see* Gritz et al, 201  
—*see* Pond et al, 183  
Bergstrom RF, Kay DR, Harkcom TM, Wagner JG: Penicillamine kinetics in normal subjects, 404  
Bertilsson L: *see* Mellström et al, 189  
Bianchine JR: *see* Foulds et al, 693

- Birkett DJ: *see* Grygiel and Birkett, 491  
Bixler EO: *see* Kales et al, 194  
Bjornsson TD: *see* Brown et al, 636  
Blumenthal HP: *see* Colburn et al, 559  
Bobik A, Jennings G, Skews H, Esler M, McLean A: Low oral bioavailability of dihydroergotamine and first-pass extraction in patients with orthostatic hypotension, 673  
—*see* Jackman et al, 291  
—*see* McLean et al, 31  
Bochner F, Graham GG, Cham BE, Imhoff DM, Haavisto TM: Salicylate metabolite kinetics after several salicylates, 266  
Bodey GP: *see* Estey et al, 398  
Boelaert J: *see* Hallynck et al, 414  
Boobis AR: *see* Brodie et al, 363  
Boyd ND: *see* Kinniburgh and Boyd, 276  
Branch RA: *see* Verbeek et al, 619  
Bravo EL: *see* Fouad et al, 782  
Breckenridge AM: *see* Edwards et al, 551  
Brodie MJ, Boobis AR, Hillyard CJ, Abeyasekera G, MacIntyre I, Park BK: Effect of isoniazid on vitamin D metabolism and hepatic monooxygenase activity, 363  
Brooks CS: *see* Bauer et al, 35  
Brown AS: *see* Rickels et al, 95  
Brown JE, Kitchell BB, Bjornsson TD, Shand DG: The artifactual nature of heparin-induced drug protein-binding alterations, 636  
Brown JL: *see* Chrysant et al, 600  
Brown N: *see* Estey et al, 398  
Buch J: *see* Waldorff et al, 172  
Buntinx AP: *see* Tobert et al, 385  
Burch RN: *see* Bauer et al, 35  
Buskin JN: *see* Williams et al, 226  
Busto U: *see* Naranjo et al, 239

#### C

- Campbell SC, Lauver GL, Cobb RB Jr: Central ventilatory depression by oral propranolol, 758  
Carruthers SG, Twum-Barima Y: Measurement of partial agonist activity of pindolol, 581  
Cato AE: *see* Zusman et al, 251

- Cavanaugh JH: *see* Stoll et al, 605  
 Cham BE: *see* Bochner et al, 266  
 Chiang ST: *see* Murray et al, 805  
 Chrysant SG, Miller RP, Brown JL, Danisa K:  
 Long-term hemodynamic and metabolic effects of trimazosin in essential hypertension, 600  
 Chu L-C: *see* Hogan et al, 729  
 Clarke JM: *see* McInnes et al, 218  
 Clements JA: *see* Holt et al, 232  
 Clifton G: *see* Cruz et al, 57  
 Cobb RB Jr: *see* Campbell et al, 758  
 Cohen D: *see* Rickels et al, 95  
 Colburn WA, Bekersky I, Blumenthal HP: Dietary saccharin kinetics, 559  
 Cole AFD: *see* Elvin et al, 455  
 Connor JD: *see* de Miranda et al, 662  
 Conrad KA, Lee SM: Clodronate kinetics and dynamics, 114  
 Conradi EC: *see* Walle et al, 790  
 Copeland JG: *see* Plachetka et al, 745  
 Crow JW: *see* Zusman et al, 251  
 Cruz F, O'Neill WM Jr, Clifton G, Wallin JD: Effects of labetalol and methyldopa on renal function, 57

*D*

- Dahlström B: *see* Säwe et al, 629  
 Daneels R: *see* Hallynck et al, 414  
 Danisa K: *see* Chrysant et al, 600  
 Davies RO: *see* Green et al, 378  
 DeMaria AN: *see* Harris et al, 765  
 de Miranda P, Good SS, Laskin OL, Krasny HC, Connor JD, Leitman PS: Disposition of intravenous radioactive acyclovir, 662  
 De Rosa F: *see* Hallynck et al, 414  
 DeSchepper P: *see* Tobert et al, 385  
 Dettli L: *see* Hallynck et al, 414  
 Dahir P: *see* Rubin et al, 258  
 Dillenkoffer RL: *see* Giles et al, 724  
 Diven W: *see* Garzone et al, 86  
 Divoll M: *see* Greenblatt et al, 475  
 Dollery CT: *see* FitzGerald et al, 164  
 Domecq C: *see* Naranjo et al, 239  
 Dorph-Pedersen A: *see* Pedersen et al, 311  
 Døssing M, Andreasen PB: Ethanol and antipyrine clearance, 101  
 Dubb J: *see* Pitkin et al, 587  
 Dudley FJ: *see* McLean et al, 31  
 Dumbrell M: *see* Sandor et al, 390  
 Dustan HP: *see* Wilkins et al, 752  
 Dziedzic SW: *see* Gorkin et al, 739  
 Dziubinski J: *see* Mackenzie et al, 436

*E*

- Easler ME: *see* Ellinwood et al, 534  
 Edwards G, Awadzi K, Breckenridge AM, Gilles HM, Orme ML'E, Ward SA: Diethylcarbamazine disposition in patients with onchocerciasis, 551  
 Egeblad H: *see* Waldorff et al, 172

- Ehrlich S: *see* Pitkin et al, 587  
 Elijevich F: *see* Gorkin et al, 739  
 Elkayam U, Mathur M, Frishman W, LeJemtel T, Strom J, Sonnenblick EH: Dynamic responses to continuous use of prazosin and hydralazine in patients with refractory heart failure, 23  
 Ellinwood EH Jr, Linnoila M, Easler ME, Molter DW: Onset of peak impairment after diazepam and after alcohol, 534  
 Elvin AT, Cole AFD, Pieper JA, Rolbin SH, Lalka D: Effect of food on lidocaine kinetics: mechanism of food-related alteration in high intrinsic clearance drug elimination, 455  
 Engle MA: *see* Linday et al, 735  
 Esler M: *see* Bobik et al, 673  
 Estey EH, Weaver SS, LeBlanc BM, Brown N, Ho DH, Bodey GP: Ceforanide kinetics, 398

*F*

- Fagan TC: *see* Walle et al, 790  
 Familiar R: *see* Pitkin et al, 587  
 Fanizza AM: *see* Novick et al, 353  
 Feinstein AR: Clinical biostatistics LVI. The *t* test and the basic ethos of parametric statistical inference (Conclusion), 133  
 —Clinical biostatistics LVII. A glossary of neologisms in quantitative clinical science, 564  
 Fillastre JP: *see* Hallynck et al, 414  
 Fink M, Irwin P: Pharmacoelectroencephalographic study of brotizolam, a novel hypnotic, 336  
 Fish A: *see* Pickles et al, 303  
 FitzGerald GA, Hossman V, Dollery CT: Norepinephrine release in essential hypertension, 164  
 Fouad F, Tarazi RC, Bravo EL: Dihydroergotamine in idiopathic orthostatic hypotension: short-term intramuscular and long-term oral therapy, 782  
 Foulds G, O'Brien MM, Bianchini JR, Gabbay KH: Kinetics of an orally absorbed aldose reductase inhibitor, sorbinil, 693  
 Freedman SB, Richmond DR, Ashley JJ, Kelly DT: Verapamil kinetics in normal subjects and patients with coronary spasm, 644  
 Frishman W: *see* Elkayam et al, 23  
 Frisk-Holmberg M, Jorfeldt L, Juhlin-Dannfelt A: Metabolic effects in muscle during antihypertensive therapy with  $\beta_1$ - and  $\beta_1/\beta_2$ -adrenoceptor blockers, 611  
 Frölich JC: *see* Reimann and Frölich, 348  
 Fuller R, Hoppel C, Ingalls ST: Furosemide kinetics in patients with hepatic cirrhosis with ascites, 461

*G*

- Gabbay KH: *see* Foulds et al, 693  
 Gaffney TE: *see* Walle et al, 790  
 Gambertoglio JG: *see* Smith et al, 105

- Ganguly A, Weinberger MH: Triamterene-thiazide combination: alternative therapy for primary aldosteronism, 246
- Garland WA: *see* Miller et al, 343
- Garzone P, Lyon J, Yu VL, Zuraleff J, Diven W, Pasculle W: Steady-state moxalactam kinetics: comparisons with other cephalosporins, 86
- Gelb AM: *see* Novick et al, 353
- Giles TD, Iteld BJ, Mautner RK, Rognoni PA, Dillenkoff RL: Short-term effects of intravenous clonidine in congestive heart failure, 724
- Gilles HM: *see* Edwards et al, 551
- Glickstein S: *see* Weintraub et al, 149
- Gobuty AH: *see* Wahl et al, 506
- Goldberger V: *see* Hager et al, 283
- Goldstein M: *see* Leibowitz et al, 719
- Good SS: *see* de Miranda et al, 662
- Gopinathan G: *see* Leibowitz et al, 719
- Gorkin JU, Eljovich F, Dziedzic SW, Krakoff LR: Addition of acebutolol to diuretics in hypertension, 739
- Graham GG: *see* Bochner et al, 266
- Grahnén A, Seideman P, Lindström B, Haglund K, von Bahr C: Prazosin kinetics in hypertension, 439
- see* Seideman et al, 447
- Graves PE: *see* Hager et al, 594
- Gray JD: *see* Renton et al, 422
- Green D, Davies RO, Holmes GI, Kohl H, Lee RB, Reynolds N, Schmid FR, Ts'ao C-H: Effects of diflunisal on platelet function and fecal blood loss, 378
- Greenblatt DJ, Divoll M, Harmatz JS, MacLaughlin DS, Shader RI: Kinetics and clinical effects of flurazepam in young and elderly noninsomniacs, 475
- see* Naranjo et al, 239
- Griffiths RR: *see* Henningfield and Griffiths, 497
- Gritz ER, Baer-Weiss V, Benowitz NL, Van Vunakis H, Jarvik ME: Plasma nicotine and cotinine concentrations in habitual smokers, 201
- Grove J: *see* Haegele et al, 210
- Grygiel JJ, Birkett DJ: Cigarette smoking and theophylline clearance and metabolism, 491

## H

- Haavisto TM: *see* Bochner et al, 266
- Haegele KD, Alken RG, Grove J, Schechter PJ, Koch-Weser J: Kinetics of  $\alpha$ -difluoromethylornithine: an irreversible inhibitor of ornithine decarboxylase, 210
- Hager WD, Mayersohn M, Graves PE: Digoxin bioavailability during quinidine administration, 594
- Pieniaszek HJ Jr, Perrier D, Mayersohn M, Goldberger V: Assessment of beta blockade with propranolol, 283
- Haglund K: *see* Seideman et al, 447

- Hall TLP: *see* Tobert et al, 385
- Hallynck T, Soep HH, Thomis J, Boelaert J, Daneels R, Fillastre JP, De Rosa F, Rubinstein E, Hatala M, Spousta J, Dettli L: Prediction of creatinine clearance from serum creatinine concentration based on lean body mass, 414
- Hammill SC: *see* Shand et al, 701
- Hansen PB: *see* Waldorff et al, 172
- Harapat S: *see* Kates et al, 44
- Harkcom TM: *see* Bergstrom et al, 404
- Harmatz JS: *see* Greenblatt et al, 475
- Harris FJ, Tonkin M, Pratt C, DeMaria AN, Amsterdam EA, Mason DT: Short- and long-term therapy of mild essential hypertension with timolol, 765
- Harris H: *see* Rickels et al, 95
- Harrison DC: *see* Kates et al, 44
- Harrison IR: *see* McInnes et al, 218
- Hasday JD: *see* Weintraub et al, 528
- Hata T: *see* Ogihara et al, 328
- Hatala M: *see* Hallynck et al, 414
- Hawkins SS, Alford RH, Stone WJ, Smyth R, Pfeiffer M: Ceforanide kinetics in renal insufficiency, 468
- Heading RC: *see* Holt et al, 232
- Heimberg M: *see* Bauer et al, 35
- Hemberger JA: *see* McGraw et al, 321
- Henningfield JE, Griffiths RR: Cigarette smoking and subjective responses: effects of *d*-amphetamine, 497
- Hernández-Pieretti O: *see* Velasco et al, 158
- Hillyard CJ: *see* Brodie et al, 363
- Ho DH: *see* Estey et al, 398
- Hogan MJ, Wallin JD, Chu L-C: Plasma clonidine concentration and pharmacologic effect, 729
- Holmes GI: *see* Green et al, 378
- Holt S, Heading RC, Clements JA, Tothill P, Prescott LF: Acetaminophen absorption and metabolism in celiac disease and Crohn's disease, 232
- Hoppel C: *see* Fuller et al, 461
- Hossman V: *see* FitzGerald et al, 164
- Huber PB: *see* Tobert et al, 385
- Huempel M: *see* Kampf et al, 77
- Hung OR: *see* Renton et al, 422
- Hurowitz A: *see* Rickels et al, 95
- Hvidt S: *see* Pedersen et al, 311

## I

- Imhoff DM: *see* Bochner et al, 266
- Ingalls ST: *see* Fuller et al, 461
- Irwin P: *see* Fink and Irwin, 336
- Isbister C: *see* McLean et al, 31
- Iteld BJ: *see* Giles et al, 724

## J

- Jackman GP, McLean AJ, Jennings GL, Bobik A: No stereoselective first-pass hepatic extraction of propranolol, 291

- Jacob P: *see* Pond et al, 183  
 Jacobson EJ, Zahrowski JJ, Nissenson AR: Moxalactam kinetics in hemodialysis, 487  
 Jacoby EH: *see* Manchester and Jacoby, 687  
 Jacoby JA: *see* Kales et al, 194  
 Janecek E: *see* Naranjo et al, 239  
 —*see* Robinson et al, 71  
 Jarvik ME: *see* Gritz et al, 201  
 Jennings G: *see* Bobik et al, 673  
 Jennings GL: *see* Jackman et al, 291  
 Jones RM: *see* Williams et al, 226  
 Jorfeldt L: *see* Frisk-Holmberg et al, 611  
 Juhlin-Dannfelt A: *see* Frisk-Holmberg et al, 611

## K

- Kales A, Scharf MB, Bixler EO, Schweitzer PK, Jacoby JA, Soldatos CR: Dose-response studies of quazepam, 194  
 Kampf D, Huempel M, Lerche U, Kessel M: Effects of uremia and hemodialysis on lormetazepam disposition, 77  
 Kates RE, Keefe DLD, Schwartz J, Harapat S, Kirsten EB, Harrison DC: Verapamil disposition kinetics in chronic atrial fibrillation, 44  
 Kay DC: *see* Pickworth et al, 796  
 Kay DR: *see* Bergstrom et al, 404  
 Keefe DLD: *see* Kates et al, 44  
 Kelly DT: *see* Freedman et al, 644  
 Kessel M: *see* Kampf et al, 77  
 Kessler KM, Perez GO: Decreased quinidine plasma protein binding during hemodialysis, 121  
 Khouw V: *see* Sandor et al, 390  
 Kinniburgh DW, Boyd ND: Isolation of peptides from uremic plasma that inhibit phenytoin binding to normal plasma proteins, 276  
 Kirch W, Schäfer-Korting M, Axthelm T, Köhler H, Mutschler E: Interaction of atenolol with furosemide and calcium and aluminum salts, 429  
 Kirsten EB: *see* Kates et al, 44  
 Kitchell BB: *see* Brown et al, 636  
 Kjågård H: *see* Waldorff et al, 172  
 Klitgaard NA: *see* Pedersen et al, 311  
 Klotz U, Reimann I: Elevation of steady-state diazepam levels by cimetidine, 513  
 —*see* Allonen et al, 653  
 Kober G: *see* Woodcock et al, 52  
 Koch-Weser J: *see* Haeghe et al, 210  
 Koepke HH: *see* Murray et al, 805  
 Kohl H: *see* Green et al, 378  
 Köhler H: *see* Kirch et al, 429  
 Krakoff LR: *see* Gorkin et al, 739  
 Krasny HC: *see* de Miranda et al, 662  
 Kreek MJ: *see* Novick et al, 353  
 Kretschmar KM: *see* Pond and Kretschmar, 680  
 Kuhlmann J, Zilly W, Wilke J: Effects of cytostatic drugs on plasma level and renal excretion of  $\beta$ -acetyldigoxin, 518

- Kumahara Y: *see* Ogihara et al, 328  
 Kupersmith M: *see* Leibowitz et al, 719

## L

- Lalka D: *see* Elvin et al, 455  
 Lasagna L: *see* Weintraub et al, 149  
 Laskin OL: *see* de Miranda et al, 662  
 Lauver GL: *see* Campbell et al, 758  
 Lebert PA, MacLeod SM, Mahon WA, Soldin SJ, Vandenberghe HM: Ranitidine kinetics and dynamics. I. Oral dose studies, 539  
 —Mahon WA, MacLeod SM, Soldin SJ, Vandenberghe HM: Ranitidine kinetics and dynamics. II. Intravenous dose studies and comparison with cimetidine, 545  
 LeBlanc BM: *see* Estey et al, 398  
 Lee RB: *see* Green et al, 378  
 Lee SM: *see* Conrad and Lee, 114  
 Leiberman A: *see* Leibowitz et al, 719  
 Leibowitz M, Leiberman A, Goldstein M, Neophytides A, Kupersmith M, Gopinathan G, Mehl S: Cardiac effects of pergolide, 719  
 Leitman PS: *see* de Miranda et al, 662  
 LeJemtel T: *see* Elkayam et al, 23  
 Lemberger L: *see* Rubin et al, 258  
 Lerche U: *see* Kampf et al, 77  
 Levine LS: *see* Rifkind et al, 127  
 Levy RH: *see* Miller et al, 343  
 Lin M-S: *see* Shepherd et al, 773  
 Lindsay LA, Engle MA, Reidenberg MM: Maturation and renal digoxin clearance, 735  
 Lindenbaum EJ: *see* Rickels et al, 95  
 Lindenbaum J, Long R, Wenger T, Mallis G, Cato A: Lack of difference in digoxin urinary excretion with two intravenous infusion rates, 317  
 Lindström B: *see* Grahnen et al, 439  
 Linnoila M: *see* Ellinwood et al, 534  
 Lockwood D: *see* Weintraub et al, 528  
 Long R: *see* Lindenbaum et al, 317  
 Ludden T: *see* Shepherd et al, 773  
 Ludwick BT: *see* Miller et al, 343  
 Lukert BP: *see* Wahl et al, 506  
 Lyon J: *see* Garzone et al, 86

## M

- McGraw BF, Hemberger JA, Smith AL, Schroeder JS: Variability of exercise performance during long-term placebo treatment, 321  
 McInnes GT, Shelton JR, Asbury MJ, Harrison IR, Clarke JM, Ramsay LE, Venning GR: Bioassay of a new aldosterone antagonist and evaluation of a simple method of quantitative comparison, 218  
 MacIntyre I: *see* Brodie et al, 363  
 Mackenzie TB, Popkin MK, Dziubinski J, Sheppard JR: Effects of caffeine withdrawal on isoproterenol-stimulated cyclic adenosine monophosphate, 436  
 MacLaughlin DS: *see* Greenblatt et al, 475

- McLean A: *see* Bobik et al, 673  
 McLean AJ, Isbister C, Bobik A, Dudley FJ: Reduction of first-pass hepatic clearance of propranolol by food, 31  
 —*see* Jackman et al, 291  
 MacLeod CM: *see* Stoll et al, 605  
 MacLeod SM: *see* Lebert et al, 539, 545  
 McNay J: *see* Shepherd et al, 773  
 Mahon WA: *see* Lebert et al, 539, 545  
 Mallis G: *see* Lindenbaum et al, 317  
 Manchester DK, Jacoby EH: Sensitivity of human placental monooxygenase activity to maternal smoking, 687  
 Maruyama A: *see* Ogihara et al, 328  
 Mason DT: *see* Harris et al, 765  
 Mathur M: *see* Elkayam et al, 23  
 Mautner RK: *see* Giles et al, 724  
 Mayersohn M: *see* Hager et al, 283, 594  
 Mehl S: *see* Leibowitz et al, 719  
 Meisinger MAP: *see* Tobert et al, 385  
 Mellström B, Bertilsson L, Säwe J, Schulz H-U, Sjöqvist F: E- and Z-10-hydroxylation of nortriptyline: relationship to polymorphic debrisoquine hydroxylation, 189  
 Mikami H: *see* Ogihara et al, 328  
 Miller ME, Garland WA, Min BH, Ludwick BT, Ballard RH, Levy RH: Clonazepam acetylation in fast and slow acetylators, 343  
 Miller RF: *see* Chrysant et al, 600  
 Min BH: *see* Miller et al, 343  
 Minami M: *see* Nomura et al, 177  
 Mitchell HC, Pettinger WA: Clonidine and prazosin effects in hypernoradrenergic vasodilator-treated and  $\beta$ -blocker-treated patients, 297  
 Miyazaki K: *see* Nomura et al, 177  
 Modell W: On the significance of significant, 1 (Editorial)  
 Molter DW: *see* Ellinwood et al, 534  
 Morillo J: *see* Velasco et al, 158  
 Mullie A: *see* Tobert et al, 385  
 Murray TG, Chiang ST, Koepke HH, Walker BR: Renal disease, age, and oxazepam kinetics, 805  
 Musgrave G: *see* Shepherd et al, 773  
 Mutschler E: *see* Kirch et al, 429

# N

- Nahata M, Powell DA: Bioavailability and clearance of chloramphenicol after intravenous chloramphenicol succinate, 368  
 Naka T: *see* Ogihara et al, 328  
 Nakamaru M: *see* Ogihara et al, 328  
 Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ: A method for estimating the probability of adverse drug reactions, 239  
 Neidert GL: *see* Pickworth et al, 796  
 Neophytides A: *see* Leibowitz et al, 719  
 New MI: *see* Rifkind et al, 127  
 Nielsen-Kudsk F: *see* Pedersen et al, 311

- Nissenson AR: *see* Jacobson et al, 487  
 Nomura A, Yasuda H, Minami M, Akimoto T, Miyazaki K, Arita T: Effect of furosemide in congestive heart failure, 177  
 Novick DM, Kreek MJ, Fanizza AM, Yancovitz SR, Gelb AM, Stenger RJ: Methadone disposition in patients with chronic liver disease, 353

# O

- O'Brien MM: *see* Foulds et al, 693  
 Oexmann M-J: *see* Walle et al, 790  
 Ogihara T, Maruyama A, Hata T, Mikami H, Nakamaru M, Naka T, Ohde H, Kumahara Y: Hormonal responses to long-term converting enzyme inhibition in hypertensive patients, 328  
 Ohde H: *see* Ogihara et al, 328  
 O'Neill WM Jr: *see* Cruz et al, 57  
 Oparil S: *see* Wilkins et al, 752  
 Orme ML'E: *see* Edwards et al, 551

# P

- Paalzow L: *see* Säwe et al, 629  
 Pareira J: *see* Rifkind et al, 127  
 Park BK: *see* Brodie et al, 363  
 Pasculle W: *see* Garzone et al, 86  
 Passananti GT: *see* Pirolì et al, 810  
 Pedersen KE, Dorph-Pedersen A, Hvidt S, Klitgaard NA, Nielsen-Kudsk F: Digoxin-verapamil interaction, 311  
 Perez GO: *see* Kessler and Perez, 121  
 Perrier D: *see* Hager et al, 283  
 Perucca E: *see* Pickles et al, 303  
 Pettinger WA: *see* Mitchell and Pettinger, 297  
 Pfeffer M: *see* Hawkins et al, 468  
 Pickles H, Perucca E, Fish A, Richens A: Propranolol and sotalol as antagonists of isoproterenol-enhanced physiologic tremor, 303  
 Pickworth WB, Neidert GL, Kay DC: Morphinelike arousal by methadone during sleep, 796  
 Pieniaszek HJ Jr: *see* Hager et al, 283  
 Pieper JA: *see* Elvin et al, 455  
 Pirolì RJ, Passananti GT, Shively C, Vesell ES: Antipyrine and warfarin disposition in a patient with idiopathic hypoalbuminemia, 810  
 Pitkin D, Dobb J, Actor P, Alexander F, Ehrlich S, Familiar R, Stote R: Kinetics and renal handling of cefonicid, 587  
 Plachetka JR, Salomon NW, Copeland JG: Plasma propranolol before, during, and after cardiopulmonary bypass, 745  
 Pond SM, Kretschmar KM: Effect of phenytoin on meperidine clearance and normeperidine formation, 680  
 —Tong T, Benowitz NL, Jacob P, Rigod J: Presystemic metabolism of meperidine to normeperidine in normal and cirrhotic subjects, 183

- Popkin MK: *see* Mackenzie et al, 436  
Powell DA: *see* Nahata and Powell, 368  
Pratt C: *see* Harris et al, 765  
Prescott LF: *see* Holt et al, 232  
Pritchett EC: *see* Shand et al, 701

## R

- Ramírez A: *see* Velasco et al, 158  
Ramsay LE: *see* McInnes et al, 218  
Rane A: *see* Säwe et al, 629  
Reichgott MJ: Minoxidil and pericardial effusion: an idiosyncratic reaction, 64  
Reidenberg MM: *see* Linday et al, 735  
Reimann I: *see* Klotz and Reimann, 513  
Reimann IW, Frölich JC: Effects of diclofenac on lithium kinetics, 348  
Reitbrock N: *see* Woodcock et al, 52  
Renton KW, Gray JD, Hung OR: Depression of theophylline elimination by erythromycin, 422  
Reynolds N: *see* Green et al, 378  
Richens A: *see* Pickles et al, 303  
Richmond DR: *see* Freedman et al, 644  
Rickels K, Brown AS, Cohen D, Harris H, Hurowitz A, Lindenbaum EJ, Ross HA, Weinstock R, Wiseman K, Zal M: Clobazam and diazepam in anxiety, 95  
Rifkind AB, Saenger P, Levine LS, Pareira J, New MI: Effects of growth hormone on antipyrine kinetics in children, 127  
Rigod J: *see* Pond et al, 183  
Roberts EA: *see* Naranjo et al, 239  
Robinson GM, Sellers EM, Jenecek E: Barbiturate and hypnosedative withdrawal by a multiple oral phenobarbital loading dose technique, 71  
Rognoni PA: *see* Giles et al, 724  
Rolbin SH: *see* Elvin et al, 455  
Ross HA: *see* Rickels et al, 95  
Routledge PA, Shand DG, Barchowsky A, Wagner G, Stargel WW: Relationship between  $\alpha_1$ -acid glycoprotein and lidocaine disposition in myocardial infarction, 154  
Rubin A, Lemberger L, Dhahir P: Physiologic disposition of pergolide, 258  
Rubinstein E: *see* Hallynck et al, 414  
Ruiz I: *see* Naranjo et al, 239

## S

- Saenger P: *see* Rifkind et al, 127  
Salomon NW: *see* Plachetka et al, 745  
Sandor P, Sellers EM, Dumbrell M, Khouw V: Effect of short- and long-term alcohol use on phenytoin kinetics in chronic alcoholics, 390  
—*see* Naranjo et al, 239  
Säwe J, Dahlström B, Paalzow L, Rane A: Morphine kinetics in cancer patients, 629  
—*see* Mellström et al, 189

- Schäfer-Korting M: *see* Kirch et al, 429  
Scharf MB: *see* Kales et al, 194  
Schechter PJ: *see* Haegele et al, 210  
Schmid FR: *see* Green et al, 378  
Schroeder JS: *see* McGraw et al, 321  
Schulz H-U: *see* Mellström et al, 189  
Schulz W: *see* Woodcock et al, 52  
Schwartz J: *see* Kates et al, 44  
Schweitzer PK: *see* Kales et al, 194  
Seideman P, Grahnen A, Haglund K, Lindström B, von Vahr C: Prazosin dynamics in hypertension: relationship to plasma concentration, 447  
—*see* Grahnen et al, 439  
Sellers EM: *see* Naranjo et al, 239  
—*see* Robinson et al, 71  
—*see* Sandor et al, 390  
Shader RI: *see* Greenblatt et al, 475  
Shand DG, Hammill SC, Aanonsen L, Pritchett EC: Reduced verapamil clearance during long-term oral administration, 701  
—*see* Brown et al, 636  
—*see* Routledge et al, 154  
Shelton JR: *see* McInnes et al, 218  
Shepherd A, Lin M-S, McNay J, Ludden T, Musgrave G: Determinants of response to intravenous hydralazine in hypertension, 773  
Sheppard JR: *see* Mackenzie et al, 436  
Shively C: *see* Piroli et al, 810  
Sjoerdsma A: Suicide enzyme inhibitors as potential drugs, 3 (Commentary)  
Sjöqvist F: *see* Mellström et al, 189  
Skews H: *see* Bobik et al, 673  
Smith AL: *see* McGraw et al, 321  
Smith DE, Gambertoglio JG, Vincenti F, Benet LZ: Furosemide kinetics and dynamics after kidney transplant, 105  
Smith LR: *see* Wilkins et al, 752  
Smyth R: *see* Hawkins et al, 468  
Soep HH: *see* Hallynck et al, 414  
Soldatos CR: *see* Kales et al, 194  
Soldin SJ: *see* Lebert et al, 539, 545  
Sonnenblick EH: *see* Elkayam et al, 23  
Spousta J: *see* Hallynck et al, 414  
Stargel WW: *see* Routledge et al, 154  
Steiness E: *see* Waldorff et al, 172  
Stenger RJ: *see* Novick et al, 353  
Stoll RW, Cavanaugh JH, MacLeod CM: Beta-blocking effect of single oral doses of carteolol, 605  
Stone WJ: *see* Hawkins et al, 468  
Stote R: *see* Pitkin et al, 587  
Strom J: *see* Elkayam et al, 23

## T

- Tarazi RC: *see* Fouad et al, 782  
Taves DR: *see* Weintraub et al, 528  
Thomis J: *see* Hallynck et al, 414  
Tjandramaga TB: *see* Tobert et al, 385



- Tobert JA, DeSchepper P, Tjandramaga TB, Mullie A, Buntinx AP, Meisinger MAP, Huber PB, Hall TLP, Yeh KC: Effect of antacids on the bioavailability of diflunisal in the fasting and postprandial states, 385  
Tolkoff-Rubin N: *see* Zusman et al, 251  
Tong T: *see* Pond et al, 183  
Tonkin M: *see* Harris et al, 765  
Tothill P: *see* Holt et al, 232  
Ts'ao CH: *see* Green et al, 378  
Twum-Barima Y: *see* Carruthers and Twum-Barima, 581

U

- Upton RA: *see* Williams et al, 226  
Urbina-Quintana A: *see* Velasco et al, 158

V

- Van Vunakis H: *see* Gritz et al, 201  
Vandenbergh HM: *see* Lebert et al, 539, 545  
Velasco M, Andrews-Figueroa P, Ramírez A, Morillo J, Urbina-Quintana A, Aliendres R, Hernández-Pieretti O: Systemic and cardiac hemodynamic interactions between clonidine and minoxidil, 158  
Venning GR: *see* McInnes et al, 218  
Verbeeck RK, Branch RA, Wilkinson GR: Meperidine disposition in man: influence of urinary pH and route of administration, 619  
Vesell ES: *see* Piroli et al, 801  
Vincenti F: *see* Smith et al, 105  
von Bahr C: *see* Grahnen et al, 439  
—*see* Seideman et al, 447

W

- Wagner G: *see* Routledge et al, 154  
Wagner JG: *see* Bergstrom et al, 404  
Wahl TO, Gobuty AH, Lukert BP: Long-term anticonvulsant therapy and intestinal calcium absorption, 506  
Waldorff S, Hansen PB, Kjägård H, Buch J, Egeblad H, Steiness E: Amiloride-induced changes in digoxin dynamics and kinetics: abolition of digoxin-induced inotropism with amiloride, 172  
Walker BR: *see* Murray et al, 805  
Walle T, Fagan TC, Walle UK, Oexmann M-J, Conradi EC, Gaffney TE: Food-induced increase in propranolol bioavailability—relationship to protein and effects on metabolites, 790

- Walle UK: *see* Walle et al, 790  
Wallin JD: *see* Cruz et al, 57  
—*see* Hogan et al, 729  
Walter U: Red blood cell sodium and potassium after hydrochlorothiazide, 373  
—Effect of ouabain and furosemide on erythrocyte sodium and phosphate transport, 709  
Ward SA: *see* Edwards et al, 551  
Weaver SS: *see* Estey et al, 398  
Weinberger MH: *see* Ganguly and Weinberger, 246  
Weinstein I: *see* Bauer et al, 35  
Weinstock R: *see* Rickels et al, 95  
Weintraub M, Glickstein S, Lasagna L: Estrogen patient package insert: medication acceptance despite negative attitudes, 149 (Commentary)  
—Taves DR, Hasday JD, Lockwood D: Determinants of response to anorexics, 528  
Wenger T: *see* Lindenbaum et al, 317  
Wilcox HH: *see* Bauer et al, 35  
Wilke J: *see* Kuhlmann et al, 518  
Wilkins LH, Winternitz SR, Oparil S, Smith LR, Dustan HP: Lofexidine and clonidine in moderate essential hypertension, 752  
Wilkinson GR: *see* Verbeeck et al, 619  
Williams RL, Upton RA, Buskin JN, Jones RM: Ketoprofen-aspirin interactions, 226  
Winternitz SR: *see* Wilkins et al, 752  
Wiseman K: *see* Rickels et al, 95  
Woodcock BG, Schulz W, Kober G, Reitbrock N: Direct determination of hepatic extraction of verapamil in cardiac patients, 52

Y

- Yancovitz SR: *see* Novick et al, 353  
Yasuda H: *see* Nomura et al, 177  
Yeh KC: *see* Tobert et al, 385  
Yu VL: *see* Garzone et al, 86

Z

- Zahrowski JJ: *see* Jacobson et al, 487  
Zal M: *see* Rickels et al, 95  
Ziegler G: *see* Allonen et al, 653  
Zilly W: *see* Kuhlmann et al, 518  
Zuraleff J: *see* Garzone et al, 86  
Zusman RM, Crow JW, Cato AE, Tolkoff-Rubin N: Effects of prostacyclin infusion in uremic patients: hematologic and hemodynamic responses, 251

## Subject index

### A

- Absorption, acetaminophen, and metabolism in celiac disease and Crohn's disease (Holt et al), 232
- Acebutolol, addition of, to diuretics in hypertension (Gorkin et al), 739
- Acetaminophen absorption and metabolism in celiac disease and Crohn's disease (Holt et al), 232
- Acetylation, clonazepam, in fast and slow acetylators (Miller et al), 343
- Acetylators, fast and slow, clonazepam acetylation in (Miller et al), 343
- $\beta$ -Acetyldigoxin, renal excretion and plasma level of, effects of cytostatic drugs on (Kuhlmann et al), 518
- $\alpha_1$ -Acid glycoprotein and lidocaine disposition, relationship between, in myocardial infarction (Routledge et al), 154
- Acyclovir, intravenous radioactive, disposition of (de Miranda et al), 662
- Adenosine monophosphate, isoproterenol-stimulated, effects of caffeine withdrawal on (Mackenzie et al), 436
- Adrenoceptor blockers,  $\beta_1$ - and  $\beta_1/\beta_2$ -, antihypertensive therapy with, metabolic effects in muscle during (Frisk-Holmberg et al), 611
- Age, renal disease, and oxazepam kinetics (Murray et al), 805
- Agonist activity, partial, of pindolol, measurement of (Carruthers and Twum-Barima), 581
- Alcohol and diazepam, onset of peak impairment after (Ellinwood et al), 534
- use, short- and long-term, effect of, on phenytoin kinetics in chronic alcoholics (Sandor et al), 390
- Alcoholics, chronic, phenytoin kinetics in, effect of short- and long-term alcohol use on (Sandor et al), 390
- Aldose reductase inhibitor (sorbitol), orally absorbed, kinetics of (Foulds et al), 693
- Aldosterone antagonist, bioassay of new, and evaluation of simple method of quantitative comparison (McInnes et al), 218
- Aldosteronism, primary, alternative therapy for: triamterene-thiazide combination (Ganguly and Weinberger), 246
- Aluminum and calcium salts and furosemide, interaction of atenolol with (Kirch et al), 429
- American Society for Clinical Pharmacology and Therapeutics, notes of, 147, 281, 704, 817
- Amiloride-induced changes in digoxin dynamics and kinetics: abolition of digoxin-induced inotropism with amiloride (Waldorff et al), 172
- d*-Amphetamine, effects of: cigarette smoking and subjective response (Henningfield and Griffiths), 497
- Anorexants, determinants of response to (Weintraub et al), 528
- Antacids, effect of, on bioavailability of diflunisal in fasting and postprandial states (Tobert et al), 385
- Antagonist(s), aldosterone, bioassay of new, and evaluation of simple method of quantitative comparison (McInnes et al), 218
- pranolol and sotalol as, of isoproterenol-enhanced physiologic tremor (Pickles et al), 303
- Anticonvulsant therapy, long-term, and intestinal calcium absorption (Wahl et al), 506
- Antihypertensive therapy with  $\beta_1$ - and  $\beta_1/\beta_2$ -adrenoceptor blockers, metabolic effects in muscle during (Frisk-Holmberg et al), 611
- Antipyrine clearance, ethanol and (Døssing and Andresen), 101
- kinetics in children, effects of growth hormone on (Rifkind et al), 127
- and warfarin disposition in patient with idiopathic hypoalbuminemia (Piroli et al), 810
- Arousal, morphinelike, by methadone during sleep (Pickworth et al), 796
- Artery spasm, coronary, patients with, verapamil kinetics in normal subjects and (Freedman et al), 644
- Artificial nature of heparin-induced drug protein-binding alterations (Brown et al), 636

- Ascites, hepatic cirrhosis with, furosemide kinetics in patients with (Fuller et al), 461  
Aspirin-ketoprofen interactions (Williams et al), 226  
Atenolol, interaction of, with furosemide and calcium and aluminum salts (Kirch et al), 429  
Atrial fibrillation, chronic, verapamil disposition kinetics in (Kates et al), 44  
Attitudes, negative, medication acceptance despite: estrogen patient package insert (Weintraub et al), 149 (Commentary)

## B

- Barbiturate and hypnosedative withdrawal by multiple oral phenobarbital loading dose technique (Robinson et al), 71  
Beta blockade, assessment of, with propranolol (Hager et al), 283  
—blocking effect of single oral doses of carteolol (Stoll et al), 605  
Binding, protein-, alterations, heparin-induced drug, artifactual nature of (Brown et al), 636  
Bioassay of new aldosterone antagonist and evaluation of simple method of quantitative comparison (McInnes et al), 218  
Bioavailability and clearance of chloramphenicol after intravenous chloramphenicol succinate (Nahata and Powell), 368  
of diflunisal, effect of antacids on, in fasting and postprandial states (Tobert et al), 385  
digoxin, during quinidine administration (Hager et al), 594  
low oral, of dihydroergotamine and first-pass extraction in patients with orthostatic hypotension (Bobik et al), 673  
propranolol, food-induced increase in—relationship to protein and effects on metabolites (Walle et al), 790  
Biostatistics, clinical, LVI. T test and basic ethos of parametric statistical inference (Conclusion) (Feinstein), 133 (Clinical biostatistics)  
LVII. Glossary of neologisms in quantitative clinical science (Feinstein), 564  
Blockade, beta, assessment of, with propranolol (Hager et al), 283  
Blocker(s),  $\beta_1$ - and  $\beta_1/\beta_2$ -adrenoceptor, antihypertensive therapy with, metabolic effects in muscle during (Frisk-Holmberg et al), 611  
—treated,  $\beta$ -, and hyperadrenergic vasodilator-treated patients, clonidine and prazosin effects in (Mitchell and Pettinger), 297  
Blocking, beta-, effect of, of single oral doses of carteolol (Stoll et al), 605  
Blood cell, red, sodium and potassium after hydrochlorothiazide (Walter), 373  
loss, fecal, and platelet function, effects of diflunisal on (Green et al), 378  
Body mass, lean, serum creatinine concentration based on, prediction of creatinine clearance from (Hallynck et al), 414

- Brotizolam, novel hypnotic, pharmacoecephalographic study of (Fink and Irwin), 336

## C

- Caffeine withdrawal, effects of, on isoproterenol-stimulated cyclic adenosine monophosphate (Mackenzie et al), 436  
Calcium absorption, intestinal, long-term anticonvulsant therapy and (Wahl et al), 506  
and aluminum salts and furosemide, interaction of atenolol with (Kirch et al), 429  
Cancer patients, morphine kinetics in (Säwe et al), 629  
Cardiac effects of pergolide (Leibowitz et al), 719  
patients, direct determination of hepatic extraction of verapamil extraction in (Woodcock et al), 52  
and systemic hemodynamic interactions between clonidine and minoxidil (Velasco et al), 158  
Cardiopulmonary bypass, plasma propranolol before, during, and after (Plachetka et al), 745  
Carteolol, beta-blocking effect of single oral doses of (Stoll et al), 605  
Cefonicid, kinetics and renal handling of (Pitkin et al), 587  
Ceforanide kinetics (Estey et al), 398  
in renal insufficiency (Hawkins et al), 468  
Celiac disease and Crohn's disease, acetaminophen absorption and metabolism in (Holt et al), 232  
Cephalosporins, comparisons with other: steady-state moxalactam kinetics (Garzone et al), 86  
Children, antipyrine kinetics in, effects of growth hormone on (Rifkind et al), 127  
Chloramphenicol, bioavailability and clearance of, after intravenous chloramphenicol succinate (Nahata and Powell), 368  
Cigarette smoking and subjective response: effects of *d*-amphetamine (Henningfield and Griffiths), 497  
and theophylline clearance and metabolism (Grygiel and Birkett), 491  
Cimetidine, comparison with, intravenous dose studies and, II. Ranitidine kinetics and dynamics (Lebert et al), 545  
elevation of steady-state diazepam levels by (Klotz and Reimann), 513  
Cirrhosis, hepatic, with ascites, furosemide kinetics in patients with (Fuller et al), 461  
Cirrhotic and normal subjects, presystemic metabolism of meperidine to normeperidine in (Pond et al), 183  
Clearance and bioavailability of chloramphenicol after intravenous chloramphenicol succinate (Nahata and Powell), 368  
creatinine, prediction of, from serum creatinine concentration based on lean body mass (Hallynck et al), 414

- Clearance—cont'd  
 ethanol and antipyrine (Døssing and Andreasen), 101  
 first-pass hepatic, of propranolol, reduction of, by food (McLean et al), 31  
 meperidine, and normeperidine formation, effect of phenytoin on (Pond and Kretschmar), 680  
 and metabolism, theophylline, cigarette smoking and (Grygiel and Birkett), 491  
 reduced verapamil, during long-term oral administration (Shand et al), 701  
 renal digoxin, maturation and (Linday et al), 735  
 Clinical biostatistics LVI. t Test and basic ethos of parametric statistical inference (Conclusion) (Feinstein), 133 (Clinical biostatistics)  
 LVII. Glossary of neologisms in quantitative clinical science (Feinstein), 564  
 Pharmacology and Therapeutics, American Society for: *see* American Society for Clinical Pharmacology and Therapeutics  
 Clobazam and diazepam in anxiety (Rickels et al), 95  
 Clodronate kinetics and dynamics (Conrad and Lee), 114  
 Clonazepam acetylation in fast and slow acetylators (Miller et al), 343  
 Clonidine concentration, plasma, and pharmacologic effect (Hogan et al), 729  
 intravenous, short-term effects of, in congestive heart failure (Giles et al), 724  
 and lofexidine in moderate essential hypertension (Wilkins et al), 752  
 and minoxidil, systemic and hemodynamic interactions between (Velasco et al), 158  
 and prazosin effects in hypernoradrenergic vasodilator-treated and  $\beta$ -blocker-treated patients (Mitchell and Pettinger), 297  
 Congestive heart failure, effect of furosemide in (Nomura et al), 177  
 short-term effects of intravenous clonidine in (Giles et al), 724  
 Coronary artery spasm, patients with, verapamil kinetics in normal subjects and (Freedman et al), 644  
 Cotinine and nicotine concentrations, plasma, in habitual smokeless tobacco users (Gritz et al), 201  
 Creatinine clearance, prediction of, from serum creatinine concentration based on lean body mass (Hallynck et al), 414  
 Crohn's disease and celiac disease, acetaminophen absorption and metabolism in (Holt et al), 232  
 Cytostatic drugs, effects of, on plasma level and renal excretion of  $\beta$ -acetyldigoxin (Kuhlmann et al), 518
- D
- Debrisoquine hydroxylation, polymorphic, relationship to: E- and Z-10-hydroxylation of nortriptyline (Mellström et al), 189  
 Decarboxylase, ornithine, irreversible inhibitor of: kinetics of  $\alpha$ -defluoromethylornithine (Haegele et al), 210  
 Diazepam and clobazam in anxiety (Rickels et al), 95  
 levels, steady-state, elevation of, by cimetidine (Klotz and Reimann), 513  
 onset of peak impairment after, and after alcohol (Ellinwood et al), 534  
 Diclofenac, effects of, on lithium kinetics (Reimann and Frölich), 348  
 Dietary saccharin kinetics (Colburn et al), 559  
 Diethylcarbamazine disposition in patients with onchocerciasis (Edwards et al), 551  
 Diflunisal, bioavailability of, effect of antacids on, in fasting and postprandial states (Tobert et al), 385  
 effects of, on platelet function and fecal blood loss (Green et al), 378  
 $\alpha$ -Difluoromethylornithine, kinetics of: irreversible inhibitor of ornithine decarboxylase (Haegele et al), 210  
 Digoxin bioavailability during quinidine administration (Hager et al), 594  
 clearance, renal, maturation and (Linday et al), 735  
 dynamics and kinetics, amiloride-induced changes in: abolition of digoxin-induced inotropism with amiloride (Waldorff et al), 172  
 urinary excretion, lack of difference in, with two intravenous infusion rates (Lindenbaum et al), 317  
 -verapamil interaction (Pedersen et al), 313  
 Dihydroergotamine in idiopathic orthostatic hypotension: short-term intramuscular and long-term oral therapy (Fouad et al), 782  
 low oral bioavailability of, and first-pass extraction in patients with orthostatic hypotension (Bobik et al), 673  
 Disposition: *see* specific drug  
 Diuretic(s) in hypertension, addition of acetbutolol to (Gorkin et al), 739  
 and propranolol, effects of, on plasma lipoprotein lipids (Bauer et al), 35  
 Dose-response studies of quazepam (Kales et al), 194  
 Drug(s): *see* also specific drug name  
 reactions, adverse, method for estimating probability of (Naranjo et al), 239  
 suicide inhibitors as potential (Sjoerdsma et al), 3 (Commentary)
- E
- E- and Z-10-hydroxylation of nortriptyline: relationship to polymorphic debrisoquine hydroxylation (Mellström et al), 189  
 Effusion, pericardial, and minoxidil: idiosyncratic reaction (Reichgott), 64  
 Elimination, high intrinsic clearance drug, mechanism of food-related alterations in: effect of food on lidocaine kinetics (Elvin et al), 455  
 theophylline, depression of, by erythromycin (Renton et al), 422

- Enzyme inhibition, long-term converting, hormonal responses to, in hypertensive patients (Ogihara et al), 328
- suicide, inhibitors, as potential drugs (Sjoerdsma), 3 (Commentary)
- Erythrocyte sodium and phosphate transport, effect of ouabain and furosemide on (Walter), 709
- Erythromycin, depression of theophylline elimination by (Renton et al), 422
- Essential hypertension, long-term hemodynamic and metabolic effects of trimazosin in (Chrysant et al), 600
- mild, short- and long-term therapy of, with timolol (Harris et al), 765
- moderate, lofexidine and clonidine in (Wilkins et al), 752
- norepinephrine release in (FitzGerald et al), 164
- Estimating probability of adverse drug reactions, method for (Naranjo et al), 239
- Estrogen patient package insert: medication acceptance despite negative attitudes (Weintraub et al), 149 (Commentary)
- Ethanol and antipyrine clearance (Døssing and Andreassen), 101
- Ethos, basic, of parametric statistical inference, t test and (Conclusion) (Feinstein), 133 (Clinical biostatistics)
- Excretion, digoxin urinary, lack of difference in, with two intravenous infusion rates (Lindenbaum et al), 317
- Exercise performance, variability of, during long-term placebo treatment (McGraw et al), 321
- Extraction, first-pass, low oral bioavailability of dihydroergotamine and, in patients with orthostatic hypotension (Bobik et al), 673
- hepatic, of verapamil, direct determination of, in cardiac patients (Woodcock et al), 52
- no stereoselective first-pass hepatic, of propranolol (Jackman et al), 291
- F**
- Fasting and postprandial states, effect of antacids on bioavailability of diflunisal in the (Tobert et al), 385
- Fecal blood loss and platelet function, effects of diflunisal on (Green et al), 378
- First-pass extraction, low oral bioavailability of dihydroergotamine and, in patients with orthostatic hypotension (Bobik et al), 673
- hepatic clearance of propranolol, reduction of, by food (McLean et al), 31
- extraction, no stereoselective, of propranolol (Jackman et al), 291
- Flurazepam, kinetics and clinical effects of, in young and elderly noninsomniacs (Greenblatt et al), 475
- Food, effect of, on lidocaine kinetics: mechanism of food-related alterations in high intrinsic clearance drug elimination (Elvin et al), 455

- Food—cont'd
- induced increase in propranolol bioavailability—relationship to protein and effects on metabolites (Walle et al), 790
- reduction of first-pass hepatic clearance of propranolol by (McLean et al), 31
- Furosemide and calcium and aluminum salts, interaction of atenolol with (Kirch et al), 429
- effect of, in congestive heart failure (Nomura et al), 177
- kinetics and dynamics after kidney transplant (Smith et al), 105
- in patients with hepatic cirrhosis with ascites (Fuller et al), 461
- and ouabain, effect of, on erythrocyte sodium and phosphate transport (Walter), 709

**G**

- Glossary of neologisms in quantitative clinical science (Feinstein), 564 (Clinical biostatistics)
- Glycoprotein,  $\alpha_1$ -acid, and lidocaine disposition relationship between, in myocardial infarction (Routledge et al), 154
- Growth hormone, effects of, on antipyrine kinetics in children (Rifkind et al), 127

**H**

- Heart failure, congestive, effect of furosemide in (Nomura et al), 177
- short-term effects of intravenous clonidine in (Giles et al), 724
- refractory, patients with, dynamic responses to continuous use of prazosin and hydralazine in (Elkayam et al), 23
- Hematologic and hemodynamic responses: effects of protacyclin infusion in uremic patients (Zusman et al), 251
- Hemodialysis, decreased quinidine plasma protein binding during (Kessler and Perez), 121
- moxalactam kinetics in (Jacobson et al), 487
- and uremia, effects of, on lormetazepam disposition (Kampf et al), 77
- Hemodynamic and hematologic responses: effects of prostacyclin infusion in uremic patients (Zusman et al), 251
- interactions, systemic and cardiac, between clonidine and minoxidil (Velasco et al), 158
- and metabolic effects, long-term, of trimazosin in essential hypertension (Chrysant et al), 600
- Heparin-induced drug protein-binding alterations, artifactual nature of (Brown et al), 636
- Hepatic cirrhosis with ascites, furosemide kinetics in patients with (Fuller et al), 461
- clearance, first-pass, of propranolol, reduction of, by food (McLean et al), 31
- extraction, direct determination of, of verapamil in cardiac patients (Woodcock et al), 52
- no stereoselective first-pass, of propranolol (Jackman et al), 291

- Hepatic cirrhosis—cont'd  
  monooxygenase activity and vitamin D metabolism, effect of isoniazid on (Brodie et al), 363
- Hormonal responses to long-term converting enzyme inhibition in hypertensive patients (Ogihara et al), 328
- Hydralazine, intravenous, in hypertension, determinants of response to (Shepherd et al), 773  
  and prazosin, dynamic responses to continuous use of, in patients with refractory heart failure (Elkayam et al), 23
- Hydrochlorothiazide, red blood cell sodium and potassium after (Walter), 373
- Hydroxylation, E- and Z-10-, of nortriptyline: relationship to polymorphic debrisoquine hydroxylation (Mellström et al), 189
- Hypenoreadrenergic vasodilator—treated and  $\beta$ -blocker—treated patients, clonidine and prazosin effects in (Mitchell and Pettinger), 297
- Hypertension, determinants of response to intravenous hydralazine in (Shepherd et al), 773  
  diuretics in, addition of acebutolol to (Gorkin et al), 739  
  essential, long-term hemodynamic and metabolic effects of trimazosin in (Chysant et al), 600  
  norepinephrine release in (FitzGerald et al), 164  
  mild essential, short- and long-term therapy of, with timolol (Harris et al), 765  
  moderate essential, lofexidine and clonidine in (Wilkins et al), 752  
  prazosin dynamics in: relationship to plasma concentration (Seideman et al), 447  
  kinetics in (Grahnen et al), 439
- Hypertensive patients, hormonal responses in, to long-term converting enzyme inhibition (Ogihara et al), 328
- Hypnosedative and barbiturate withdrawal by multiple oral phenobarbital loading dose technique (Robinson et al), 71
- Hypnotic, novel, pharmacoecephalographic study of brotizolam (Fink and Irwin), 336
- Hypoalbuminemia, idiopathic, antipyrine and warfarin disposition in patient with (Pirolì et al), 810
- Hypotension, idiopathic orthostatic, dihydroergotamine in: short-term intramuscular and long-term oral therapy (Fouad et al), 782  
  orthostatic, patients with, low oral bioavailability of dihydroergotamine and first-pass extraction in (Bobik et al), 673
- I
- Idiopathic hypoalbuminemia, antipyrine and warfarin disposition in patient with (Pirolì et al), 810  
  orthostatic hypotension, dihydroergotamine in: short-term intramuscular and long-term oral therapy (Fouad et al), 782
- Idiosyncratic reaction: minoxidil and pericardial effusion (Reichgott), 64
- Infarction, myocardial, relationship between  $\alpha_1$ -acid glycoprotein and lidocaine disposition in (Routledge et al), 154
- Infusion, prostacyclin, effects of, in uremic patients: hematologic and hemodynamic responses (Zusman et al), 251  
  rates, intravenous, lack of difference in digoxin urinary excretion with (Lindenbaum et al), 317
- Inhibition, long-term converting enzyme, hormonal responses to, in hypertensive patients (Ogihara et al), 328
- Inhibitor(s), orally absorbed aldose reductase (sorbinil), kinetics of (Foulds et al), 693  
  irreversible, of ornithine decarboxylase: kinetics of  $\alpha$ -difluoromethylornithine (Haegele et al), 210  
  suicide enzyme, as potential drugs (Sjoerdsma), 3 (Commentary)
- Inotropism with amiloride, abolition of digoxin-induced: amiloride-induced changes in digoxin dynamics and kinetics (Waldorff et al), 172
- Insert, estrogen patient package: medication acceptance despite negative attitudes (Weintraub et al), 149 (Commentary)
- Intestinal calcium absorption, long-term anticonvulsant therapy and (Wahl et al), 506
- Intramuscular therapy, short-term, and long-term oral: dihydroergotamine in idiopathic orthostatic hypotension (Fouad et al), 782
- Intravenous chloramphenicol succinate, bioavailability and clearance of chloramphenicol after (Nahata and Powell), 368  
  clonidine, short-term effects of, in congestive heart failure (Giles et al), 724  
  dose studies and comparison with cimetidine, II. Ranitidine kinetics and dynamics (Lebert et al), 545  
  hydralazine in hypertension, determinants of response to (Shepherd et al), 773  
  infusion rates, two, lack of difference in digoxin urinary excretion with (Lindenbaum et al), 317  
  radioactive acyclovir, disposition of (de Miranda et al), 662
- Isoniazid, effect of, on vitamin D metabolism and hepatic monooxygenase activity (Brodie et al), 363
- Isoproterenol-enhanced physiologic tremor, propranolol and sotalol as antagonists of (Pickles et al), 303  
  -stimulated cyclic adenosine monophosphate, effects of caffeine withdrawal on (Mackenzie et al), 436
- K
- Ketoprofen-aspirin interactions (Williams et al), 226  
  Kinetics: *see* specific drug



*L*

- Labetalol and methyldopa, effects of, on renal function (Cruz et al), 57
- Lidocaine disposition and  $\alpha_1$ -acid glycoprotein, relationship between, in myocardial infarction (Routledge et al), 154
- kinetics, effect of food on: mechanism of food-related alterations in high intrinsic clearance drug elimination (Elvin et al), 455
- Lipids, plasma lipoprotein, effects of diuretic and propranolol on (Bauer et al), 35
- Lipoprotein lipids, plasma, effects of diuretic and propranolol on (Bauer et al), 35
- Lithium kinetics, effects of diclofenac on (Reimann and Frölich), 348
- Liver disease, chronic, methadone disposition in patients with (Novick et al), 353
- Loading dose technique, phenobarbital, multiple oral, barbiturate and hypnosedative withdrawal by (Robinson et al), 71
- Lofexidine and clonidine in moderate essential hypertension (Wilkins et al), 752
- Lormetazepam disposition, effects of uremia and hemodialysis on (Kampf et al), 77

*M*

- Maternal smoking, sensitivity of human placental monooxygenase activity to (Manchester and Jacoby), 687
- Maturation and renal digoxin clearance (Linday et al), 735
- Medication acceptance despite negative attitudes: estrogen patient package insert (Weintraub et al), 149 (Commentary)
- Meperidine clearance and normeperidine formation, effect of phenytoin on (Pond and Kretschmar), 680
- disposition in man: influence of urinary pH and route of administration (Verbeeck et al), 619
- presystemic metabolism of, to normeperidine in normal and cirrhotic subjects (Pond et al), 183
- Metabolic effects in muscle during antihypertensive therapy with  $\beta_1$ - and  $\beta_1/\beta_2$ -adrenoceptor blockers (Frisk-Holmberg et al), 611
- and hemodynamic effects, long-term, of trimazolin in essential hypertension (Chrysant et al), 600
- Metabolism, acetaminophen absorption and, in celiac disease and Crohn's disease (Holt et al), 232
- and clearance, theophylline, cigarette smoking and (Grygiel and Birkett), 491
- presystemic, of meperidine to normeperidine in normal and cirrhotic subjects (Pond et al), 183
- vitamin D, and hepatic monooxygenase activity, effect of isoniazid on (Brodie et al), 363

- Metabolite(s), effects on, and protein, relationship to: food-induced increase in propranolol bioavailability (Walle et al), 790
- kinetics, salicylate, after several salicylates (Bochner et al), 266
- Methadone disposition in patients with chronic liver disease (Novick et al), 353
- morphinelike arousal by, during sleep (Pickworth et al), 796
- Methyldopa and labetalol, effects of, on renal function (Cruz et al), 57
- Midazolam kinetics (Allonen et al), 653
- Minoxidil and clonidine, systemic and hemodynamic interactions between (Velasco et al), 158
- and pericardial effusion: idiosyncratic reaction (Reichgott), 64
- Monooxygenase activity, hepatic, and vitamin D metabolism, effect of isoniazid on (Brodie et al), 363
- human placental, sensitivity of, to maternal smoking (Manchester and Jacoby), 687
- Monophosphate, adenosine, isoproterenol-stimulated, effects of caffeine withdrawal on (Mackenzie et al), 436
- Morphine kinetics in cancer patients (Säwe et al), 629
- Morphinelike arousal by methadone during sleep (Pickworth et al), 796
- Moxalactam kinetics in hemodialysis (Jacobson et al), 487
- steady-state: comparisons with other cephalosporins (Garzone et al), 86
- Muscle, metabolic effects in, during antihypertensive therapy with  $\beta_1$ - and  $\beta_1/\beta_2$ -adrenoceptor blockers (Frisk-Holmberg et al), 611
- Myocardial infarction, relationship between  $\alpha_1$ -acid glycoprotein and lidocaine disposition in (Routledge et al), 154

*N*

- Neologisms, glossary of, in quantitative clinical science (Feinstein), 564 (Clinical biostatistics)
- Nicotine and cotinine concentrations, plasma, in habitual smokeless tobacco users (Gritz et al), 201
- Noninsomniacs, young and elderly, kinetics and clinical effects of flurazepam in (Greenblatt et al), 475
- Norepinephrine release in essential hypertension (FitzGerald et al), 164
- Normeperidine formation, and meperidine clearance, effect of phenytoin on (Pond and Kretschmar), 680
- presystemic metabolism of meperidine to, in normal and cirrhotic subjects (Pond et al), 183
- Nortriptyline, E- and Z-10-hydroxylation of: relationship to polymorphic debrisoquine hydroxylation (Mellström et al), 189

*O*

- Onchocerciasis, diethylcarbamazine disposition in patients with (Edwards et al), 551
- Oral administration, long-term, reduced verapamil during (Shand et al), 701
- bioavailability, low, of dihydroergotamine and first-pass extraction in patients with orthostatic hypotension (Bobik et al), 673
- dose(s) of carteolol, single, beta-blocking effect of (Stoll et al), 605
- studies, I. Ranitidine kinetics and dynamics (Lebert et al), 539
- propranolol, central ventilatory depression by (Campbell et al), 758
- therapy, long-term, and short-term intramuscular: dihydroergotamine in idiopathic orthostatic hypotension (Fouad et al), 782
- Ornithine decarboxylase, irreversible inhibitor of: kinetics of  $\alpha$ -difluoro methylornithine (Haegele et al), 210
- Orthostatic hypotension, idiopathic, dihydroergotamine in: short-term intramuscular and long-term oral therapy (Fouad et al), 782
- patients with, low oral bioavailability of dihydroergotamine and first-pass extraction in (Bobik et al), 673
- Ouabain and furosemide, effect of, on erythrocyte sodium and phosphate transport (Walter), 709
- Oxazepam kinetics, renal disease, and age (Murray et al), 805

*P*

- Parametric statistical inference, basic ethos of, t test and (Conclusion) (Feinstein), 133 (Clinical biostatistics)
- Patient package insert, estrogen: medication acceptance despite negative attitudes (Weintraub et al), 149 (Commentary)
- Penicillamine kinetics in normal subjects (Bergstrom et al), 404
- Peptides, isolation of, from uremic plasma that inhibit phenytoin binding to normal plasma proteins (Kinniburgh and Boyd), 276
- Pergolide, cardiac effects of (Leibowitz et al), 719
- physiologic disposition of (Rubin et al), 258
- Pericardial effusion, and minoxidil: idiosyncratic reaction (Reichgott), 64
- pH, urinary, and route of administration, influence of: meperidine disposition in man (Verbeeck et al), 619
- Pharmacoencephalographic study of brotizolam, novel hypnotic (Fink and Irwin), 336
- Pharmacology, Clinical, and Therapeutics, American Society for: see American Society for Clinical Pharmacology and Therapeutics
- Phenobarbital loading dose technique, multiple oral, barbiturate and hypnosedative withdrawal by (Robinson et al), 71
- Phenytoin binding to normal plasma proteins, isolation of peptides from uremic plasma that inhibit (Kinniburgh and Boyd), 276
- effect of, on meperidine clearance and normeperidine formation (Pond and Kretschmar), 680
- kinetics in chronic alcoholics, effect of short- and long-term alcohol use on (Sandor et al), 390
- Phosphate transport and erythrocyte sodium, effect of ouabain and furosemide on (Walter), 709
- Physiologic disposition of pergolide (Rubin et al), 258
- tremor, isoproterenol-enhanced, propranolol and sotalol as antagonists of (Pickles et al), 303
- Pindolol, measurement of partial agonist activity of (Carruthers and Twum-Barima), 581
- Placebo treatment, long-term, variability of exercise performance during (McGraw et al), 321
- Placental monooxygenase activity, human, sensitivity of, to maternal smoking (Manchester and Jacoby), 687
- Plasma clonidine concentration and pharmacologic effect (Hogan et al), 729
- concentration, relationship to: prazosin dynamics in hypertension (Seideman et al), 447
- lipoprotein lipids, effects of diuretic and propranolol on (Bauer et al), 35
- nicotine and cotinine concentrations in habitual smokeless tobacco users (Gritz et al), 201
- propranolol before, during, and after cardiopulmonary bypass (Plachetka et al), 745
- protein binding, quinidine, decreased, during hemodialysis (Kessler and Perez), 121
- uremic, isolation of peptides from, that inhibit phenytoin binding to normal plasma proteins (Kinniburgh and Boyd), 276
- Platelet function and fecal blood loss, effects of diflunisal on (Green et al), 378
- Polymorphic debrisoquine hydroxylation, relationship to: E- and Z-10-hydroxylation of nortriptyline (Mellström et al), 189
- Postprandial and fasting states, effect of antacids on the bioavailability of diflunisal in (Tobert et al), 385
- Potassium and sodium, red blood cell, after hydrochlorothiazide (Walter), 373
- Prazosin and clonidine effects in hypernoradrenergic vasodilator-treated and  $\beta$ -blocker-treated patients (Mitchell and Pettinger), 297
- dynamics in hypertension: relationship to plasma concentration (Seideman et al), 447
- and hydralazine, dynamic responses to continuous use of, in patients with refractory heart failure (Elkayam et al), 23
- kinetics in hypertension (Grahnen et al), 439
- Presystemic metabolism of meperidine to normeperidine in normal and cirrhotic subjects (Pond et al), 183



- Propranolol, assessment of beta blockade with (Hager et al), 283  
bioavailability, food-induced increase in—relationship to protein and effects on metabolites (Walle et al), 790  
and diuretic, effects of, on plasma lipoprotein lipids (Bauer et al), 35  
no stereoselective first-pass hepatic extraction of (Jackman et al), 291  
oral, central ventilatory depression by (Campbell et al), 758  
plasma, before, during, and after cardiopulmonary bypass (Plachetka et al), 745  
reduction of first-pass hepatic clearance of, by food (McLean et al), 31  
and sotalol as antagonists of isoproterenol-enhanced physiologic tremor (Pickles et al), 303  
Prostacyclin infusion, effects of, in uremic patients: hematologic and hemodynamic responses (Zusman et al), 251  
Protein-binding alterations, heparin-induced drug, artifactual nature of (Brown et al), 636  
decreased, plasma quinidine during hemodialysis (Kessler and Perez), 121  
relationship to, and effects on metabolites,—food-induced increase in propranolol bioavailability (Walle et al), 790

Q

- Quantitative comparison, evaluation of simple method of and bioassay of new aldosterone antagonist (McInnes et al), 218  
Quazepam, dose-response studies of (Kales et al), 194  
Quinidine plasma protein binding, decreased, during hemodialysis (Kessler and Perez), 121

R

- Radioactive acyclovir, intravenous, disposition of (de Miranda et al), 662  
Ranitidine kinetics and dynamics. I. Oral dose studies (Lebert et al), 539  
II. Intravenous dose studies and comparison with cimetidine (Lebert et al), 545  
Reductase inhibitor, aldose, orally absorbed, kinetics of (sorbitol) (Foulds et al), 693  
Renal digoxin clearance, maturation and (Lindsay et al), 735  
disease, age, and oxazepam kinetics (Murray et al), 805  
excretion and plasma level of  $\beta$ -acetyldigoxin, effects of cytostatic drugs on (Kuhlmann et al), 518  
function, effects of labetalol and methyl dopa on (Cruz et al), 57  
handling and kinetics of cefonicid (Pitkin et al), 587  
insufficiency, ceforanide kinetics in (Hawkins et al), 468

- Route of administration and urinary pH, influence of: meperidine disposition in man (Verbeeck et al), 619

S

- Saccharin kinetics, dietary (Colburn et al), 559  
Salicylate metabolite kinetics after several salicylates (Bochner et al), 266  
Serum creatinine concentration based on lean body mass, prediction of creatinine clearance from (Hallynck et al), 414  
Significance of significant, on (Modell), 1 (Editorial)  
Sleep, morphinelike arousal by methadone during (Pickworth et al), 796  
Smokeless tobacco users, habitual, plasma nicotine and cotinine concentrations in (Gritz et al), 201  
Smoking, cigarette, and subjective response: effects of *d*-amphetamine (Henningfield and Griffiths), 497  
and theophylline clearance and metabolism (Grygiel and Birkett), 491  
maternal, sensitivity of human placental monooxygenase activity to (Manchester and Jacoby), 687  
Sodium, erythrocyte, and phosphate transport, effect of ouabain and furosemide on (Walter), 709  
and potassium, red blood cell, after hydrochlorothiazide (Walter), 373  
Sorbitol, kinetics of orally absorbed aldose reductase inhibitor (Foulds et al), 693  
Sotalol and propranolol as antagonists of isoproterenol-enhanced physiologic tremor (Pickles et al), 303  
Spasm, coronary artery, patients with, verapamil kinetics in normal subjects and (Freedman et al), 644  
Statistical inference, parametric, basic ethos of, *t* test and (Conclusion) (Feinstein), 133 (Clinical biostatistics)  
Steady-state diazepam levels, elevation of, by cimetidine (Klotz and Reimann), 513  
moxalactam kinetics: comparisons with other cephalosporins (Garzone et al), 86  
Stereoselective first-pass hepatic extraction, no, of propranolol (Jackman et al), 291  
Succinate, chloramphenicol, intravenous, bioavailability and clearance of chloramphenicol after (Nahata and Powell), 368  
Suicide enzyme inhibitors as potential drugs (Sjoerdsma), 3 (Commentary)  
Systemic and cardiac hemodynamic interactions between clonidine and minoxidil (Velasco et al), 158

T

- t* Test and basic ethos of parametric statistical inference (Conclusion) (Feinstein), 133 (Clinical biostatistics)

- Theophylline clearance and metabolism, cigarette smoking and (Grygiel and Birkett), 491  
elimination, depression of, by erythromycin (Renton et al), 422
- Therapeutics, Clinical Pharmacology and, American Society for: *see* American Society for Clinical Pharmacology and Therapeutics
- Therapy, alternative, for primary aldosteronism: triamterene-thiazide combination (Ganguly and Weinberger), 246  
short-term intramuscular and long-term oral: dihydroergotamine in idiopathic orthostatic hypotension (Fouad et al), 782  
and long-term, of mild essential hypertension with timolol (Harris et al), 765
- Thiazide-triamterene combination: alternative therapy for primary aldosteronism (Ganguly and Weinberger), 246
- Timolol, short- and long-term therapy of mild essential hypertension with (Harris et al), 765
- Tobacco users, habitual smokeless, plasma nicotine and cotinine concentrations in (Gritz et al), 201
- Transplant, kidney, furosemide kinetics and dynamics after (Smith et al), 105
- Tremor, isoproterenol-enhanced physiologic, propranolol and sotalol as antagonists of (Pickles et al), 303
- Triamterene-thiazide combination: alternative therapy for primary aldosteronism (Ganguly and Weinberger), 246
- Trimazosin, long-term hemodynamic and metabolic effects of, in essential hypertension (Chrysant et al), 600
- U*
- Uremia and hemodialysis, effects of, on lorazepam disposition (Kampf et al), 77
- Uremic patients, effects of prostacyclin infusion in: hematologic and hemodynamic responses (Zusman et al), 251  
plasma, isolation of peptides from, that inhibit phenytoin binding to normal plasma proteins (Kinniburgh and Boyd), 276
- Urinary excretion, digoxin, lack of difference in, with two intravenous infusion rates (Lindenbaum et al), 317  
pH and route of administration, influence of: meperidine disposition in man (Verbeeck et al), 619
- USAN Council list of new names, 427, 579, 707, 819
- V*
- Vasodilator-treated, hypernoradrenergic, and  $\beta$ -blocker-treated patients, clonidine and prazosin effects in (Mitchell and Pettinger), 297
- Ventilatory depression, central, by oral propranolol (Campbell et al), 758
- Verapamil clearance, reduced, during long-term oral administration (Shand et al), 701  
-digoxin interaction (Pedersen et al), 313  
disposition kinetics in chronic atrial fibrillation (Kates et al), 44  
hepatic extraction of, direct determination of, in cardiac patients (Woodcock et al), 52  
kinetics in normal subjects and patients with coronary artery spasm (Freedman et al), 644
- Vitamin D metabolism and hepatic monooxygenase activity, effect of isoniazid on (Brodie et al), 363
- W*
- Warfarin and antipyrine disposition in patient with idiopathic hypoalbuminemia (Piroli et al), 810
- Withdrawal, barbiturate and hypnosedative, by multiple oral phenobarbital loading dose technique (Robinson et al), 71  
caffeine, effects of, on isoproterenol-stimulated cyclic adenosine monophosphate (MacKenzie et al), 436
- Z*
- Z-10-hydroxylation, E- and, of nortriptyline: relationship to polymorphic debrisoquine hydroxylation (Mellström et al), 189

